First-day skin risk assessment outperformed vasoactive exposure in the ICU cohort
In critically ill adults who began vasoactive support within 24 hours of ICU admission, the earliest bedside pressure injury assessment carried more prognostic weight than the vasopressor dose itself. The study drew on the MIMIC-IV database and included 17,148 adult ICU stays that remained in the unit alive and free of documented injury at 24 hours, a design that sharpened the question to what clinicians can learn early enough to act on it.
Pressure injury developed in 1,833 stays, or 10.7% of the cohort. The outcome was not treated as a simple yes-or-no event in isolation. Investigators used a cause-specific Cox model with death and discharge as competing events, then entered peak norepinephrine-equivalent dose, duration of vasoactive support, hypotension burden, and the Braden Scale measured in the first 24 hours into the same model. In that head-to-head comparison, the first-day Braden score showed the largest standardized association with later pressure injury, with a hazard ratio of 0.77 per standard deviation, ahead of hypotension burden at 1.10 and peak dose at 1.07.
The bedside implication is immediate. A careful early pressure injury assessment appears to convey more practical prognostic information than the highest vasopressor dose reached during the first day.
Why the Braden score carried more signal than peak dose
The finding makes biological sense. Vasopressors can intensify peripheral vasoconstriction and reduce tissue perfusion, especially in patients already struggling with shock, edema, immobility, and impaired microcirculation. Yet pressure injury formation in the ICU is rarely the product of a single hemodynamic variable. Skin and deep tissue damage emerge from overlapping forces: pressure loading, friction, moisture, nutrition, level of mobility, sensory perception, and the patient’s overall physiologic reserve. The Braden scale captures several of those dimensions at once, which likely explains why it tracked later injury more strongly than a single exposure measure such as peak norepinephrine-equivalent dose.
Dose alone also misses timing. A transient vasopressor surge may matter less than prolonged dependence on support, especially when tissue perfusion remains unstable over time. The model results fit that clinical logic: peak dose offered a weaker association than the composite bedside score, while duration of support remained relevant in the analysis of more severe lesions.
The first week was where the associations clustered
Exploratory analyses concentrated the signal in the first week after ICU admission, when tissue vulnerability, hemodynamic instability, and immobility all tend to be most intense. During that period, the skin and underlying soft tissue are exposed to repeated compression and impaired oxygen delivery, so early risk stratification has a direct operational purpose. A short interval between admission and injury also means prevention has to start early, before the first ulcer is documented and before the opportunity for offloading, repositioning, and protective devices is lost.
For lesions severe at first documentation, most of which were deep tissue injuries, the relationship with peak dose became unclear after full adjustment, including first-day illness severity. Duration of support still carried signal in that setting. This pattern suggests that the cumulative burden of shock and support may matter more than a single maximum dose when the injury is already advanced. Deep tissue injury often reflects sustained ischemic stress rather than a brief hemodynamic dip, so the result fits the pathophysiology.
Whole-stay summaries can distort early prognostic value
A 48-hour landmark analysis added another practical caution. When investigators summarized exposure over the whole stay, the Braden association was inflated by 58%. That is a useful warning for ICU research and for bedside interpretation alike. Once a patient has already spent more time in the unit, the score may be indirectly capturing later changes in condition, care intensity, or immobility that were not present at the first assessment. Early risk tools are most useful when they reflect the state of the patient at the time prevention decisions are made, not after the clinical course has already evolved.
This matters for workflow. Nurses and intensivists often have access to both a formal skin risk tool and vasoactive dose data, but the study argues against assuming that hemodynamic exposure should eclipse structured nursing assessment. If the first-day Braden score is stronger than peak dose, then prevention bundles should not wait for vasopressor numbers to settle before being activated.
What ICU teams can do with this information
The study does not suggest that vasoactive support is irrelevant. Instead, it places vasopressor exposure in context. Shock severity, hypotension burden, and support duration all remain clinically meaningful, but they do not replace the information already embedded in a thorough Braden Scale assessment. For ICU teams, the message is to treat the first 24 hours as the decisive window for prevention planning: pressure redistribution, skin surveillance, moisture control, turning schedules adapted to hemodynamic tolerance, and heightened attention to patients with low Braden scores.
A retrospective single-centre design cannot prove causality, and the cohort comes from MIMIC-IV rather than a randomized prevention trial. Even so, the size of the dataset and the competing-risk approach give the results real clinical weight. The study also leaves open a narrower, actionable question: whether targeted prevention based on early Braden scoring can reduce the burden of ICU-acquired pressure injury more effectively than strategies triggered mainly by vasopressor dose thresholds.